Kiora Pharmaceuticals Inc
KPRX
Company Profile
Business description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Contact
332 Encinitas Boulevard
Suite 102
EncinitasCA92024
USAT: +1 858 224-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12
Stocks News & Analysis
stocks
Weekly earnings wrap: Last week’s winners & losers
A mixed first week for company’s reporting on the ASX. Here’s everything you need to know
stocks
Alphabet earnings: Continued momentum on cloud and search as capital expenses set to mount
Strong fourth quarter earnings.
stocks
Eli Lilly earnings: Revenue increases reflect global demand for oral obesity therapies
We’ve raised our fair value estimate of Lilly stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.60 | 104.20 | -1.15% |
| CAC 40 | 8,214.63 | 23.54 | -0.29% |
| DAX 40 | 24,537.69 | 46.63 | 0.19% |
| Dow JONES (US) | 49,053.22 | 448.08 | -0.91% |
| FTSE 100 | 10,301.41 | 7.81 | -0.08% |
| HKSE | 26,559.95 | 325.29 | -1.21% |
| NASDAQ | 22,540.59 | 363.99 | -1.59% |
| Nikkei 225 | 54,253.68 | 435.64 | 0.81% |
| NZX 50 Index | 13,444.02 | 23.27 | -0.17% |
| S&P 500 | 6,821.72 | 61.00 | -0.89% |
| S&P/ASX 200 | 8,708.80 | 96.70 | -1.10% |
| SSE Composite Index | 4,065.58 | 10.33 | -0.25% |